Latest Healthcare News

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.

nib Group reported a 6.2% revenue increase to $3.8 billion and a 9.1% rise in underlying operating profit to $260.9 million for FY26, despite a 5.9% net profit dip. The company achieved maiden profitability in Health Services and declared a fully franked 21c dividend including a 5c special, supported by ongoing Travel insurance divestments.

Ansell Limited (ASX:ANN) reported a robust FY26 with net profit doubling to US$208.6 million, driven by strong sales growth and operational resilience amid geopolitical challenges. The company also announced a leadership change and reaffirmed its sustainability ambitions.

BCAL Diagnostics has updated investors on its $10 million convertible note facility, revealing $7.6 million drawn to date with further funding contingent on upcoming shareholder approval.

Audeara Limited has raised $1.26 million through a two-tranche share placement to back its expanding technology licensing and retail channels, following a year of revenue growth and reduced cash burn.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Pro Medicus' US arm, Visage Imaging, has landed a substantial 7-year, A$25 million contract to deploy its Visage 7 cloud-based imaging platform across Valley Health's hospital network in Virginia and West Virginia.

Fisher & Paykel Healthcare has raised its full-year net profit guidance for FY2027, buoyed by robust first-half sales and a $23 million US tariff refund. The medical devices maker forecasts up to 24% profit growth in H1, driven by hospital product demand and operational efficiencies.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.